These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37043660)

  • 1. Renin-Angiotensin System Inhibition in Advanced CKD.
    Speth RC
    N Engl J Med; 2023 Apr; 388(15):1436-1437. PubMed ID: 37043660
    [No Abstract]   [Full Text] [Related]  

  • 2. Renin-Angiotensin System Inhibition in Advanced CKD.
    Fu EL; Tomlinson LA; Carrero JJ
    N Engl J Med; 2023 Apr; 388(15):1437-1438. PubMed ID: 37043662
    [No Abstract]   [Full Text] [Related]  

  • 3. Renin-Angiotensin System Inhibition in Advanced CKD.
    Sealey JE; Blumenfeld JD
    N Engl J Med; 2023 Apr; 388(15):1437. PubMed ID: 37043661
    [No Abstract]   [Full Text] [Related]  

  • 4. Renin-Angiotensin System Inhibition in Advanced CKD. Reply.
    Bhandari S; Cockwell P
    N Engl J Med; 2023 Apr; 388(15):1438. PubMed ID: 37043663
    [No Abstract]   [Full Text] [Related]  

  • 5. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
    Weinberger MH; Luft FC
    Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease.
    Leon SJ; Tangri N
    Can J Cardiol; 2019 Sep; 35(9):1220-1227. PubMed ID: 31472818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of renin-angiotensin system blockade in advanced CKD: to use or not to use?
    Mukoyama M; Kuwabara T
    Hypertens Res; 2022 Jun; 45(6):1072-1075. PubMed ID: 35361929
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of the renin-angiotensin-aldosterone system: how to obtain this.
    Pende A; Montecucco F
    Curr Pharm Des; 2012; 18(7):950-1. PubMed ID: 22283769
    [No Abstract]   [Full Text] [Related]  

  • 9. Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease.
    Toto R; Palmer BF
    Am J Nephrol; 2008; 28(3):372-80. PubMed ID: 18073461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.
    Vaduganathan M; Vardeny O; Michel T; McMurray JJV; Pfeffer MA; Solomon SD
    N Engl J Med; 2020 Apr; 382(17):1653-1659. PubMed ID: 32227760
    [No Abstract]   [Full Text] [Related]  

  • 11. The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease.
    Oh YJ; Kim SM; Shin BC; Kim HL; Chung JH; Kim AJ; Ro H; Chang JH; Lee HH; Chung W; Lee C; Jung JY
    PLoS One; 2017; 12(1):e0170874. PubMed ID: 28122064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW; Liu JS; Hung SC; Kuo KL; Chang YK; Chen YC; Hsu CC; Tarng DC
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Should renin-angiotensin-aldosterone system inhibition enablement be a therapeutic target in CKD patients?
    Rossignol P; Agarwal R
    Nephrol Dial Transplant; 2021 Sep; 36(10):1771-1772. PubMed ID: 33677569
    [No Abstract]   [Full Text] [Related]  

  • 14. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
    Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
    PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Need to continue or discontinue RAS inhibitors as CKD stage advances? Any alternative?
    Fujimoto D; Kuwabara T; Mukoyama M
    Hypertens Res; 2023 Aug; 46(8):2048-2050. PubMed ID: 37253978
    [No Abstract]   [Full Text] [Related]  

  • 16. Angiotensin-converting enzyme inhibitor or Angiotensin receptor blocker use and renal outcomes-reply.
    Hsu CC; Liu JS; Tarng DC
    JAMA Intern Med; 2014 Oct; 174(10):1706-7. PubMed ID: 25285739
    [No Abstract]   [Full Text] [Related]  

  • 17. Is there added value to adding ARB to ACE inhibitors in the management of CKD?
    Cohen DL; Townsend RR
    J Am Soc Nephrol; 2009 Aug; 20(8):1666-8. PubMed ID: 18776118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use and renal outcomes: prevalent user designs may overestimate benefit.
    Tomlinson L; Smeeth L
    JAMA Intern Med; 2014 Oct; 174(10):1706. PubMed ID: 25285737
    [No Abstract]   [Full Text] [Related]  

  • 19. An ACE in the hole for patients with advanced chronic kidney disease?
    Park M; Hsu CY
    JAMA Intern Med; 2014 Mar; 174(3):355-6. PubMed ID: 24342932
    [No Abstract]   [Full Text] [Related]  

  • 20. Renin-angiotensin system: Targeting multiple RAS genes.
    Carney EF
    Nat Rev Nephrol; 2014 Sep; 10(9):482. PubMed ID: 25072120
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.